Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis

Chest

Volumn 111, Issue 2, 1997, Pages 419-426

  Pilz, Günter ^a   Appel, Roland ^a   Kreuzer, Eckart ^a   Werdan, Karl ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

APACHE II score; cardiac surgery; IgM; immunoglobulin therapy; response to therapy; risk assessment; sepsis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; OPEN HEART SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0031017939     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.2.419     Document Type: Article

References (36)

1. Miholic J, Hudec.M, Domanig E, et al. Risk factors for severe bacterial infections after valve replacement and aortocoronary bypass operations: analysis of 246 cases by logistic regression. Ann Thorac Surg 1985; 40:224-28
2. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86:845-57
3. Eskola J, Salo M, Viljanen MK, et al. Impaired B lymphocyte function during open heart surgery: effects of anaesthesia and surgery. Br J Anaesth 1984; 56:333-38
4. Kharazmi A, Andersen LW, Baek L, et al. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 98:381-85
5. Ståhle E, Bergström R, Holmberg L, et al. Risk factors for operative mortality and morbidity in patients undergoing coronary artery bypass surgery for stable angina pectoris. Eur Heart J 1991;12:162-68
6. Abdelnoor M, Nitter-Hauge S, Trettli S. Relative survival of patients alter heart valve replacement. Eur Heart J 1990; 11:23-8
7. Kreuzer E, Kääb S, Pilz G, et al. Early prediction of septic complications after cardiac surgery by APACHE H score. Eur J Cardiothorac Surg 1992; 6:524-27
8. Pilz G, Kreuzer E, Kääb S, et al. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994; 105:76-82 (errata in 105:1924)
9. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29
10. Pilz G, Werdan K. Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection 1990; 18:253-62
11. Dichtelmüller H, Stephan W. Studies on the efficacy of immunoglobulin M enriched intravenous immunoglobulins against bacterial infections and in neutralization of bacterial toxins. Drug Res 1987; 37:1273-76
12. Collins MS, Hector RF, Roby RE, et al. Prophylaxis of Gram-negative and Gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with Pseudomonas immunoglobulin and ciprofloxacin. Infection 1987; 15:60-8
13. Baumgartner JD. Arguments for the administration of immunoglobulins in critically-ill patients. In: Peter K, Lawin P, Bein T, et al, eds. Intensivmedizin 1990 (vol 76). Stuttgart: Georg Thieme, 1990; 152-57
14. Cafiero F, Gipponi M, Bonalumi U, et al. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial. Surgery 1992; 112:24-31
15. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelo-suppressive therapy. Ann Intern Med 1993; 118:937-42
16. Pilz G, Gurniak T, Bujdoso O, et al. A BASIC program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 1991; 21:143-59
17. Parrillo JE. Septic shock in humans: clinical evaluation, pathogenesis, and therapeutic approach. In: Shoemaker WC, Ayres S, Grenvik A, et al., eds. Textbook of critical care. 2nd ed. Philadelphia: WB Saunders. 1989; 1006-24
18. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55
19. Elebute EA, Stoner HB. The grading of sepsis. Br J Surg 1983; 70:29-31
20. Grundmann R, Kipping N, Wesoly C. Der "Sepsisscore" von Elebute und Stoner zur definition der postoperativen sepsis auf der Intensivstation. Intensivmed 1988; 25:268-73
21. Pilz G, Fateh-Moghadam S, Viell B, et al. Supplemental immunoglobulin therapy in sepsis and septic shock - comparison of mortality under treatment with polyvalent IV immunoglobulin versus placebo: protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 1993; 8:61-83
22. Zanetti G, Glauser MP, Baumgartner JD. Use of immunoglobulins iu prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991; 13:985-92
23. Kress HG, Scheidewig C, Engelhardt W. et al. Prediction and prevention, by immunological means, of septic complications after elective cardiac surgery. Prog Clin Biol Res 1989; 308: 1031-35
24. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327:234-40
25. Dominioni L, Dionigi R, Zanello M, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126:236-40
26. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-13
27. Dalhoff A. In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 1985; 13(suppl 2):S185-91
28. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-76
29. Fink PC, Bokelmann G, Haeckel R. Antibodies against bacterial lipopolysaccharides and lipid A in immunoglobulin preparations and in sera from patients with septicaemia. Lab Med 1992; 16:319-26
30. Knaus WA, Wagner DP, Draper EA. The value of measuring severity of disease in clinical research on acutely ill patients. J Chron Dis 1984; 37:455-63
31. Haque KN, Remo C, Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol 1995; 101:328-33
32. Bion JF, Aitchison TC, Ledingham IMcA. Siekness scoring and response to treatment as predictors of outcome from critical illness. Intensive Care Med 1988; 14:167-72
33. Knaus WA, Wagner DP, Zimmerman JE, et al. Variations in mortality and length of stay in intensive care units. Ann Intern Med 1993; 118:753-61
34. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 1993; 270:1233-41
35. Petros AJ, Marshall JC, van Saene HKF. Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 1995; 345:369-71
36. Keane WF, Hirata-Dulas CAI, Bullock ML, et al. Adjunctive therapy with intravenous immunoglobulin G improves survival in patients with acute renal failure. J Am Soc Nephrol 1991; 2:841-47